Journal article

Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG

Lingyi Lu, Geraldine Cancel-Tassin, Antoine Valeri, Olivier Cussenot, Ethan M Lange, Kathleen A Cooney, James M Farnham, Nicola J Camp, Lisa A Cannon-Albright, Teuvo LJ Tammela, Johanna Schleutker, Josef Hoegel, Kathleen Herkommer, Christiane Maier, Walther Vogel, Fredrik Wiklund, Monica Emanuelsson, Henrik Groenberg, Kathleen E Wiley, Sarah D Isaacs Show all



BACKGROUND: In spite of intensive efforts, understanding of the genetic aspects of familial prostate cancer (PC) remains largely incomplete. In a previous microsatellite-based linkage scan of 1,233 PC families, we identified suggestive evidence for linkage (i.e., LOD ≥ 1.86) at 5q12, 15q11, 17q21, 22q12, and two loci on 8p, with additional regions implicated in subsets of families defined by age at diagnosis, disease aggressiveness, or number of affected members. METHODS: In an attempt to replicate these findings and increase linkage resolution, we used the Illumina 6000 SNP linkage panel to perform a genome-wide linkage scan of an independent set of 762 multiplex PC families, collected by 1..

View full abstract


Awarded by National Institutes of Health

Awarded by Cancer Research UK (CR-UK)

Awarded by National Health and Medical Research Council

Awarded by NCI Post-doctoral Fellowship in Cancer Prevention

Awarded by CeRePP: Association pour la Recherche sur le Cancer

Awarded by Academy of Finland

Awarded by University of Ulm Group: Deutsche Krebshilfe

Awarded by USPHS

Awarded by Utah Cancer Registry from the National Cancer Institute's Surveillance, Epidemiology

Awarded by Department of Defense

Awarded by Cancer Research UK





Funding Acknowledgements

Grant sponsor: National Institutes of Health; Grant number: U01 CA89600.Additional support to participating groups, or members within groups, is as follows: ACTANE Group: This study, and recruitment of UK families, was supported by Cancer Research UK (CR-UK) grant no C5047/A3354. Additional support was provided by The Prostate Cancer Research Foundation, The Times Christmas Appeal, and the Institute of Cancer Research. We thank S. Seal and A. Hall for kindly storing and logging the samples that were provided. D. F. E is a Principal Research Fellow of CR-UK. Funding in Australia was obtained from The Cancer Council Victoria, The National Health and Medical Research Council (grants 940934, 251533, 209057, 126402, 396407), Tattersall's and The Whitten Foundation. We would like to acknowledge the work of the study coordinator M. Staples and the Research Team B. McCudden, J. Connal, R. Thorowgood, C. Costa, M. Kevan, and S. Palmer, and to J. Karpowicz for DNA extractions. The Texas study of familial prostate cancer was initiated by the Department of Epidemiology, M. D. Anderson Cancer Center. M. B. was supported by an NCI Post-doctoral Fellowship in Cancer Prevention (R25). BC/CA/HI Group: USPHS CA67044. CeRePP: Association pour la Recherche sur le Cancer, grant number 5441. FHCRC Group: USPHS CA80122 (to J. L. S.) and USPHS CA78836 (to E.A.O), with additional support from the Fred Hutchinson Cancer Research Center. E.A.O and B. J. acknowledge the Intramural Program of the National Human Genome Research Institute. JHU Group: USPHS CA58236 (to W. B. I.) The generous support of William Gerrard, Mario Duhon, John and Jeniffer Chalsty, and P. Kevin Jaffe is greatly acknowledged by W. B. I. Mayo Clinic Group: USPHS CA72818. Michigan Group: USPHS CA079596. Northwestern Group: The Urological Research Foundation. University of Tampere Group: The Competitive Research Funding of the Pirkanmaa Hospital District, Reino Lahtikari Foundation, Finnish Cancer Organisations, Sigrid Juselius Foundation, and Academy of Finland grant 211123. University of Ulm Group: Deutsche Krebshilfe, grant number 70-3111-V03. Karolinska Institute Group Swedish Cancer Society and a Spear grant from the Umea University Hospital, Umea, Sweden. University of Utah Group: Data collection was supported by USPHS CA90752 (to L. A. C.-A.) and by the Utah Cancer Registry, which is funded by Contract #N01-PC-35141 from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program with additional support from the Utah State Department of Heath and the University of Utah. N.J.C. was supported in part by USPHS CA98364 (to N.J.C.). L. C. A. acknowledges support from the Huntsman Cancer Foundation. J.E.B.-W. acknowledges support from the Intrsamural Program of the National Human Genome Research Institute, NIH. DCC: The study is partially supported by USPHS CA106523 (to J. X.), USPHS CA95052 (to J. X.), and Department of Defense grant PC051264 (to J.X.).